Recently, two large-scale randomized phase III trials (RILOMET-1 study: rilotumumab, MetGastric study: onarutuzumab) evaluated the efficacy of adding HGF/MET inhibitor to first-line chemotherapy in MET-positive patients with unresectable gastric or GEJ adenocarcinoma [46, 47]. The gene discussed is HGF; the disease is gastroesophageal junction adenocarcinoma.